×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Antibody Fragment Market

ID: MRFR/HC/29384-HCR
128 Pages
Rahul Gotadki
October 2025

Antibody Fragment Market Research Report By Target (Immune System Targets, Oncology Targets, Infectious Disease Targets, Other Targets), By Format (Fab Fragments, Fv Fragments, ScFv Fragments, Other Formats), By Conjugation (Unconjugated, Drug Conjugated, Radioisotope Conjugated, Other Conjugates), By Application (Therapeutics, Diagnostics, Research Tools, Other Applications), By Source (Humanized, Chimeric, Murine, Other Sources) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

分享
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Antibody Fragment Market Infographic
Purchase Options

Antibody Fragment Market 摘要

根据MRFR的分析,抗体片段市场规模在2024年估计为554.5亿美元。抗体片段行业预计将从2025年的612.7亿美元增长到2035年的1660.1亿美元,预计在2025年至2035年的预测期内,年均增长率(CAGR)为10.48。

主要市场趋势和亮点

抗体片段市场因技术进步和对靶向疗法需求的增加而有望实现显著增长。

  • 市场对靶向疗法的需求不断上升,尤其是在北美,北美仍然是最大的市场。
  • 工程技术的进步正在提高抗体片段的疗效和特异性,特别是在肿瘤靶点方面。
  • 对研发的投资正在增加,尤其是在亚太地区,该地区被认为是增长最快的市场。
  • 慢性疾病的日益普遍和对个性化医疗的投资增加是推动市场扩张的关键因素。

市场规模与预测

2024 Market Size 554.5(亿美元)
2035 Market Size 166.01(亿美元)
CAGR (2025 - 2035) 10.48%

主要参与者

Abcam(英国),GenScript(中国),Thermo Fisher Scientific(美国),Merck KGaA(德国),Sartorius(德国),F. Hoffmann-La Roche(瑞士),Amgen (美国),Eli Lilly and Company(美国),Bristol-Myers Squibb(美国)

Antibody Fragment Market 趋势

The Antibody Fragment Market is currently experiencing a dynamic evolution, driven by advancements in biotechnology and increasing demand for targeted therapies. This market encompasses various types of antibody fragments, including single-chain variable fragments, Fab fragments, and nanobodies, which are gaining traction due to their unique properties. These fragments offer advantages such as improved tissue penetration, reduced immunogenicity, and the ability to be engineered for specific therapeutic applications. As the healthcare landscape shifts towards personalized medicine, the relevance of antibody fragments in drug development and diagnostics appears to be growing. Moreover, the rise of chronic diseases and the need for innovative treatment options are propelling research and development efforts in this sector. Pharmaceutical companies are increasingly investing in antibody fragment technologies, which may lead to the introduction of novel therapeutics. Collaborations between academic institutions and industry players are also fostering innovation, suggesting a collaborative approach to tackling complex health challenges. Overall, the Antibody Fragment Market seems poised for substantial growth, reflecting a broader trend towards precision medicine and targeted therapies in the global healthcare arena.

Rising Demand for Targeted Therapies

The Antibody Fragment Market is witnessing a surge in demand for targeted therapies, as healthcare providers seek more effective treatment options. This trend is driven by the need for therapies that minimize side effects while maximizing efficacy, particularly in oncology and autoimmune diseases.

Technological Advancements in Engineering

Innovations in biotechnology are enhancing the capabilities of antibody fragments. Techniques such as phage display and genetic engineering are enabling the development of more potent and specific fragments, which could lead to breakthroughs in therapeutic applications.

Increased Investment in Research and Development

Pharmaceutical companies are allocating more resources to research and development within the Antibody Fragment Market. This investment is likely to accelerate the discovery of new therapies and improve existing ones, reflecting a commitment to advancing healthcare solutions.

Antibody Fragment Market Drivers

诊断中的新兴应用

Emerging applications of antibody fragments in diagnostics are contributing to the growth of the Antibody Fragment Market. These fragments are being utilized in various diagnostic assays, including immunoassays and imaging techniques, due to their high specificity and sensitivity. The increasing demand for rapid and accurate diagnostic tools is driving innovation in this area. As healthcare providers seek to improve patient outcomes through early detection and monitoring, the role of antibody fragments in diagnostics is likely to expand. This trend suggests a promising future for the Antibody Fragment Market, as it diversifies its applications beyond therapeutic uses.

生物制品的监管支持

Regulatory support for biologics, including antibody fragments, appears to be a significant factor influencing the Antibody Fragment Market. Regulatory agencies are increasingly recognizing the therapeutic potential of antibody fragments, leading to streamlined approval processes and favorable guidelines. This supportive regulatory environment encourages pharmaceutical companies to invest in the development of new antibody fragment therapies. As a result, the market is likely to see an influx of innovative products, enhancing competition and driving growth within the Antibody Fragment Market. The favorable regulatory landscape may also facilitate faster patient access to novel therapies.

生物制药制造的进展

Technological advancements in biopharmaceutical manufacturing processes are likely to significantly influence the Antibody Fragment Market. Innovations such as improved cell line development, enhanced purification techniques, and the adoption of continuous manufacturing methods are streamlining production and reducing costs. These advancements facilitate the efficient production of high-quality antibody fragments, which are essential for therapeutic applications. The market is witnessing a shift towards more sustainable and scalable manufacturing practices, which could potentially increase the availability of antibody fragments. As a result, the Antibody Fragment Market is expected to benefit from these improvements, leading to a broader adoption of antibody fragment-based therapies.

慢性疾病的发病率上升

The increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases appears to be a primary driver for the Antibody Fragment Market. As these conditions become more widespread, the demand for effective therapeutic solutions intensifies. Antibody fragments, known for their specificity and reduced immunogenicity, are increasingly utilized in targeted therapies. According to recent estimates, the market for antibody-based therapies is projected to reach substantial figures, with antibody fragments playing a crucial role in this growth. The ability of these fragments to penetrate tissues more effectively than full-length antibodies enhances their appeal in treating complex diseases, thereby propelling the Antibody Fragment Market forward.

日益增长的个性化医疗投资

The growing investment in personalized medicine is a notable driver for the Antibody Fragment Market. As healthcare systems increasingly focus on tailored treatment approaches, the demand for specific and effective therapies rises. Antibody fragments, with their ability to target specific antigens, align well with the principles of personalized medicine. The market for personalized medicine is projected to expand significantly, with antibody fragments being integral to the development of customized therapies. This trend suggests that the Antibody Fragment Market will likely experience robust growth as more healthcare providers adopt personalized treatment strategies.

市场细分洞察

By Target: Immune System Targets (Largest) vs. Oncology Targets (Fastest-Growing)

The Antibody Fragment Market is predominantly driven by Immune System Targets, which hold the largest share in the market. These targets have gained significance due to the increasing prevalence of autoimmune diseases and a rising demand for therapeutic monoclonal antibodies. In contrast, Oncology Targets are rapidly gaining momentum, propelled by advancements in cancer therapies and the need for targeted treatment options. These segments cumulatively reflect a dynamic market landscape as they adapt to changing healthcare needs.

Oncology Targets: Dominant vs. Infectious Disease Targets: Emerging

Oncology Targets are recognized as the dominant segment in the Antibody Fragment Market due to their critical role in the development of innovative therapies for various types of cancer. The ongoing research and development in this area aim to enhance the specificity and effectiveness of treatments. On the other hand, Infectious Disease Targets represent an emerging segment with substantial growth potential. Driven by global health challenges such as pandemics and emerging infectious diseases, this segment is witnessing increased investments in research focused on developing effective antibody fragments that can address these urgent health needs.

按格式:Fab片段(最大)与ScFv片段(增长最快)

In the Antibody Fragment Market, Fab Fragments hold the largest market share due to their extensive applications in therapeutic and diagnostic tools. These fragments have been widely adopted in various fields, including oncology and immunology, leading to a robust demand. In contrast, ScFv Fragments are witnessing rapid growth as researchers recognize their versatility and efficiency in targeting specific antigens, making them a preferred choice for developing novel treatments.

Fragment Types: Fab Fragments (Dominant) vs. ScFv Fragments (Emerging)

Fab Fragments are highly regarded for their structural stability and ability to retain binding affinity, thereby establishing themselves as the dominant player in the market. Their wide range of applications in therapeutics contributes to their leading position. On the other hand, ScFv Fragments are emerging rapidly, particularly favored for their smaller size and ability to penetrate tissues effectively. This unique characteristic enhances their application in targeted therapies, making them a key focus area for innovation in the Antibody Fragment Market.

By Conjugation: Unconjugated (Largest) vs. Drug Conjugated (Fastest-Growing)

The antibody fragment market exhibits a diverse composition within its conjugation segment, with unconjugated fragments maintaining the largest share due to their simplicity and broad applicability in research and diagnostics. Drug conjugated fragments, while smaller in market share, have been gaining significant traction, driven by advancements in targeted therapy and personalized medicine, reflecting a growing demand for precise treatment options in oncology and other therapeutic areas. Growth trends within the conjugation segment are predominantly influenced by the increasing prevalence of cancer and the need for more effective therapies. The push toward bioconjugation techniques, particularly in drug conjugation, is reshaping the landscape by enhancing the specificity and efficacy of treatment options. Innovation in radiolabeling, such as radioisotope conjugated fragments, is also emerging, addressing a niche yet crucial area in diagnostics and therapeutic applications.

未结合(主导)与放射性同位素结合(新兴)

未结合抗体片段在市场中占据主导地位,主要由于其在各种研究和诊断领域的多功能应用。其固有的简单性使得生产容易,并广泛应用于免疫测定和成像等应用中。相比之下,放射性同位素结合片段代表了市场的新兴领域,满足了高度专业化的诊断和治疗需求,尤其是在肿瘤学方面。该细分市场的特点是放射性标记技术的创新发展,提高了治疗的有效性和精确性。尽管仍然是一个较小的细分市场,但对癌症患者靶向治疗的日益关注正在推动放射性同位素结合方面的重大进展和投资,预示着未来的良好发展轨迹。

按应用:治疗(最大)与诊断(增长最快)

在抗体片段市场中,应用细分展示了一个多样化的格局,特点是各种应用,如治疗、诊断和研究工具。治疗目前占据最大的市场份额,主要得益于其在开发靶向疗法和个性化医疗中的关键作用。相比之下,诊断在近年来经历了大量投资和创新,正迅速获得关注,成为一个快速增长的细分市场,以满足不断变化的医疗需求。

治疗学(主导)与研究工具(新兴)

治疗应用已确立其在抗体片段市场中的主导地位,专注于单克隆抗体和其他基于片段的治疗药物的开发,以应对包括癌症和自身免疫性疾病在内的各种疾病。该细分市场受益于强大的临床试验管道和治疗药物的不断批准,从而增强了投资者的信心。另一方面,研究工具应用正在崛起为一个重要参与者,受到实验室对先进生物技术解决方案日益增长的需求的推动。该细分市场以研究方法的创新为特色,使研究人员能够充分利用抗体片段在诊断和科学探索中的潜力。

按来源:人性化(最大)与嵌合体(增长最快)

抗体片段市场显示出多样化的市场份额分布,其中人源化抗体占据最大份额,因为与小鼠来源相比,它们具有更高的亲和力和更低的免疫原性。嵌合抗体也发挥着重要作用,吸引了更广泛的治疗应用。这种多方面的方法允许定制和增强治疗效果,为抗体开发的各种创新铺平了道路。

人性化(主导)与嵌合体(新兴)

人源化抗体在抗体片段市场中占据主导地位,因为它们具有优化的治疗特性,并广泛应用于包括肿瘤学和自身免疫疾病在内的各种治疗领域。它们的设计最小化了免疫反应,确保在临床环境中具有更高的疗效。另一方面,嵌合抗体作为一个快速增长的细分市场正在崛起,这得益于生物技术的进步和对研发的投资增加。这些抗体结合了小鼠和人类的元素,为靶向治疗开辟了新的途径,因此在市场未来的创新中具有相当大的潜力。

获取关于Antibody Fragment Market的更多详细见解

区域洞察

北美:引领创新与研究

北美是抗体片段最大的市场,约占全球市场份额的45%。该地区受益于先进的研究设施、对生物技术的重大投资以及鼓励创新的强大监管框架。慢性疾病的日益普遍和对个性化医疗的日益增长的需求是市场增长的主要驱动力。来自FDA等机构的监管支持进一步催化了新疗法的发展。美国是该市场的主要贡献者,主要参与者如赛默飞世尔科技、安进和礼来等公司引领着这一领域。加拿大也发挥着重要作用,专注于生物技术的研究与开发。竞争格局以关键参与者之间的合作与伙伴关系为特征,增强了创新和市场覆盖率。

欧洲:强大的监管框架

欧洲是抗体片段的第二大市场,约占全球市场份额的30%。该地区的增长得益于支持研究与开发的强大监管框架,以及对生物制药的日益投资。德国和英国等国处于前沿,专注于创新疗法和个性化医疗。欧洲药品管理局(EMA)在促进新产品市场准入方面发挥着关键作用。德国是该市场的领先国家,来自默克集团和萨托里乌斯等公司的贡献显著。英国也拥有活跃的生物技术行业,许多初创企业和成熟公司专注于抗体片段的开发。竞争格局以战略合作和并购为特征,增强了该地区的创新能力。

亚太地区:新兴市场潜力

亚太地区在抗体片段市场中正逐渐崛起,约占全球市场份额的20%。该地区由于对生物技术的投资增加、医疗支出上升和患者人口增长而迅速发展。中国和日本等国在这一增长中处于领先地位,得益于有利的政府政策和旨在增强生物制药研究与开发的举措。中国在生物技术行业的扩展尤为显著,基因科技等公司在抗体片段生产方面取得了重大进展。日本也有强大的存在,专注于创新疗法和与全球公司的合作。竞争格局正在演变,越来越多的初创企业进入市场,推动创新和竞争。

中东和非洲:未开发的市场机会

中东和非洲地区在抗体片段市场中逐渐崭露头角,约占全球市场份额的5%。增长主要受医疗需求增加、生物技术投资上升以及改善医疗基础设施的关注推动。南非和阿联酋等国在发展生物制药行业方面取得了显著进展,得益于政府旨在增强研究能力的举措。南非在该地区的市场中处于领先地位,越来越多的生物技术公司专注于抗体开发。阿联酋也在医疗创新方面进行了大量投资,为市场增长创造了良好的环境。竞争格局以本地和国际公司之间的合作为特征,旨在利用专业知识和资源以更好地渗透市场。

Antibody Fragment Market Regional Image

主要参与者和竞争洞察

抗体片段市场目前的特点是动态的竞争格局,受到创新、战略合作伙伴关系和对治疗应用的关注的驱动。主要参与者如Abcam(英国)、GenScript(中国)和Thermo Fisher Scientific(美国)处于前沿,各自采用不同的策略来增强其市场定位。Abcam(英国)强调抗体生产的创新,利用先进技术提高特异性和有效性。与此同时,GenScript(中国)专注于通过战略合作,特别是在亚洲和北美,扩大其全球足迹,以增强其服务产品。Thermo Fisher Scientific(美国)采取多元化的方法,将数字解决方案整合到其运营中,以简化流程并改善客户参与,从而塑造一个优先考虑技术进步和以客户为中心的竞争环境。

市场结构似乎适度分散,既有成熟的参与者,也有新兴公司争夺市场份额。这些公司普遍采用的关键商业策略包括本地化生产和优化供应链,使它们能够迅速响应市场需求和监管变化。主要参与者的集体影响力促进了一个竞争氛围,在这里,创新和运营效率至关重要,最终通过增强的产品和服务使最终用户受益。

2025年8月,Abcam(英国)宣布与一家领先的生物技术公司建立战略合作伙伴关系,共同开发针对肿瘤学应用的下一代抗体片段。这一合作有望利用两家公司的专业知识,可能加速新型治疗药物的开发,并巩固Abcam在抗体片段领域的领导地位。这一合作伙伴关系的战略重要性在于其增强研究能力和加快创新产品商业化的潜力。

2025年9月,GenScript(中国)推出了一个新的定制抗体片段开发平台,旨在简化研究人员和制药公司的流程。这一举措不仅展示了GenScript对创新的承诺,还解决了药物开发中对定制解决方案日益增长的需求。此次发布可能会提高客户满意度,并巩固GenScript在市场中的竞争优势。

2025年10月,Thermo Fisher Scientific(美国)推出了一种新的数字工具,旨在优化研究人员的抗体片段选择。该工具利用人工智能分析大量数据集,提供的见解可以显著减少抗体开发所需的时间。这项技术的引入反映了行业向数字化的更广泛趋势,使Thermo Fisher成为市场上前瞻性的领导者。

截至2025年10月,抗体片段市场的竞争趋势越来越受到数字化、可持续性和人工智能整合的定义。战略联盟变得越来越普遍,使公司能够汇集资源和专业知识以推动创新。展望未来,竞争差异化可能会从传统的基于价格的竞争演变为对技术进步、创新解决方案和可靠供应链的关注,强调在快速变化的市场中适应能力的重要性。

Antibody Fragment Market市场的主要公司包括

行业发展

全球抗体片段市场预计将在预测期内见证显著增长,推动因素包括慢性疾病的日益普遍、抗体工程技术的进步以及对靶向疗法的需求上升。预计到2032年,市场估值将达到1113.7亿美元,从2024年到2032年,年均增长率为10.48%。市场的最新新闻动态包括批准用于治疗各种疾病(如癌症和自身免疫性疾病)的新型抗体片段。

例如,在2023年,FDA批准了罗氏的Hemlibra,这是一种用于治疗血友病A的抗体片段。此外,研发工作集中在开发具有更高特异性、效力和稳定性的抗体片段,这预计将在未来几年进一步推动市场增长。

.webp

未来展望

Antibody Fragment Market 未来展望

The Antibody Fragment Market is projected to grow at a 10.48% CAGR from 2024 to 2035, driven by advancements in therapeutic applications and increasing demand for targeted therapies.

新机遇在于:

  • Development of bispecific antibody fragments for enhanced therapeutic efficacy.
  • Expansion into emerging markets with tailored product offerings.
  • Investment in AI-driven drug discovery platforms to streamline antibody fragment development.

By 2035, the Antibody Fragment Market is expected to achieve substantial growth, solidifying its position as a key player in biopharmaceuticals.

报告范围

MARKET SIZE 202455.45(USD Billion)
MARKET SIZE 202561.27(USD Billion)
MARKET SIZE 2035166.01(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)10.48% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesAdvancements in antibody engineering enhance therapeutic applications in the Antibody Fragment Market.
Key Market DynamicsRising demand for targeted therapies drives innovation and competition in the antibody fragment market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

发表评论

FAQs

抗体片段市场的当前估值是多少?

截至2024年,抗体片段市场的价值为554.5亿美元。

到2035年,抗体片段市场的预计市场规模是多少?

预计到2035年,市场将达到1660.1亿美元。

在预测期内,抗体片段市场的预期CAGR是多少?

抗体片段市场在2025年至2035年期间的预期CAGR为10.48%。

在抗体片段市场中,哪些公司被视为关键参与者?

主要参与者包括 Abcam、GenScript、赛默飞世尔科技、默克 KGaA、萨托里乌斯、F. 霍夫曼-拉 Roche、安进、礼来公司和百时美施贵宝。

抗体片段市场的主要细分领域是什么?

主要部分包括目标、格式、词形变化、应用和来源。

不同目标细分市场的估值如何比较?

在2024年,肿瘤学靶点的价值为200亿美元,而免疫系统靶点达到了150亿美元。

2024年Fab Fragments的市场估值是多少?

2024年,Fab Fragments的价值为200亿美元。

哪些应用正在推动抗体片段市场的增长?

治疗学在2024年的价值为221.8亿美元,是推动市场增长的主要应用。

药物偶联抗体片段的估值是多少?

药物结合抗体片段在2024年的估值为200亿美元。

市场上有哪些类型的抗体来源?

市场包括人源化、嵌合、鼠源和其他来源,其中人源化片段在2024年的价值为221.8亿美元。

下载免费样本

请填写以下表格以获取本报告的免费样本

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions